CompletedNot Applicable

Multiscale Omics for the Development of a Cohort Database and Study Platform in Breast Cancer Survivors

United States105 participantsStarted 2021-04-01

Plain-language summary

This study gathers information to create a database to improve the ability to diagnose cancer, predict long term health of breast cancer patients, and help develop future treatment products. This study will provide a foundational platform for therapeutic development and intervention studies in the future and may for therapeutic development and intervention studies in the future, and may advance researchers understanding of the contribution gut bacteria to altered circulating estrogens in breast cancer survivors.

Who can participate

Age range18 Years – 75 Years

SexFEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * BCS GROUP * Female patients diagnosed with breast cancer age 18 - 75, stages 0 through 3 at time of diagnosis * Who have completed active therapy (including surgery, radiation, and/or chemotherapy) * Able to speak English and complete surveys and provide the specimen (willing to follow the sample collection instructions) * Able to read, understand and sign inform consent * CONTROL GROUP * Healthy Volunteers age 18 - 75 * Able to speak and read English, complete consent, surveys, and provide specimens Exclusion Criteria: * Unable to give written consent * Unable to fast before providing blood and urine * Pregnant women (per participant report) and males * Unwilling to travel to Mayo Clinic Rochester to provide bio specimens

What they're measuring

Utilization of multiscale omics to build a cohort database for breast cancer survivors

Timeframe: Up to 5 years

Trial details

NCT IDNCT04999826

SponsorMayo Clinic

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2022-12-30